Project Grant R44GM148103

Award Date 6/1/23
Completion Date 11/30/25
Dollars Obligated $3M
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
State College, PA, USA
Similar Awards
This $306,872 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) aims to improve similarity scoring in drug discovery by developing a new computational method that accounts for the role of water molecules in protein-ligand binding. The award recipient, Simulations Plus Inc., will adapt their existing water prediction algorithm (WATGEN) to identify water molecules relevant for 3D shape...
This Project Grant award from the National Science Foundation's (NSF) Division of Chemistry (CFDA 47.049 - Mathematical and Physical Sciences) provides $600,000 to Arizona State University (ASU) to support theoretical modeling and computational research on the linear and nonlinear mobility of proteins, electrical conductivity of protein complexes, and the role of water at biological interfaces. The key products and services to be delivered through this 3-year award (June 2025 - May 2028)...
Quantum Simulation Technologies Inc., doing business as Qsimulate, received a $442,362 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop and validate a novel high-performance implementation of density functional theory quantum mechanics for scoring ligand-protein interactions. The award was made under the Biomedical Research and Research Training program (CFDA 93.859), which supports basic research that increases understanding of...
This Project Grant award of $175,000 from the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program (CFDA 47.070) supports the development of a modular framework for modeling the binding of peptides and proteins to cell membranes. The key products to be delivered include: A software "mover" implemented in the Rosetta C++ codebase to predict the placement of proteins and peptides in cell membranes, an application of this mover compatible...
This National Science Foundation Project Grant of $536,946 will support research at the University of California, San Diego from September 2022 through August 2025 under the Mathematical and Physical Sciences program (CFDA 47.049). The award will fund the development of rigorous scientific theories and powerful computational tools to model biomolecular interactions. Researchers will design advanced numerical methods to simulate drug and protein binding/unbinding kinetics, incorporating molecular...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to improve the quality of cryogenic electron microscopy (cryo-EM) specimens. The $349,999 award to Denovx, LLC will fund research to develop innovative surface modifications for cryo-EM specimen supports that enhance the adsorption and random orientation of biological analytes, such as proteins and protein complexes. The researchers will...
This federal Project Grant award from the National Science Foundation's Mathematical and Physical Sciences program (CFDA 47.049) totaling $349,281 supports the development of a new polarizable implicit solvent model called Polarizable-3DRISM (P3DRISM) to enable efficient and accurate molecular dynamics simulations of RNA. The principal investigators, Xuhui Huang of the University of Wisconsin, Madison and Pengyu Ren of the University of Texas, Austin, will derive a new 3DRISM equation that...
This Project Grant award of $1,012,028 from the National Institute of Environmental Health Sciences (NIEHS) under the Medical Library Assistance (CFDA 93.879) federal grant program aims to develop and validate structure-function-aware large protein language models (SF-PLM) that can be adapted for challenging biomedical research tasks through few-shot learning. The key products and services to be delivered include: (1) large protein language models that incorporate knowledge of 2D and 3D...
The National Institute of General Medical Sciences (NIGMS) awarded a $3,184,198 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to Eclipse Bioinnovations, Inc. The funding supports the development of the EMOA (Enhanced Multi-Omic Analysis) platform, a secondary drug screening service that uses both transcriptomics and translatomics to rapidly identify candidate drug compounds and elucidate their precise mechanisms of action. This project aims to shorten the drug discovery...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $360,100 to The Regents of the University of California, San Francisco to develop and test algorithms for iteratively docking subsets of ultra-large small molecule libraries against target receptors. The goal is to significantly reduce the number of molecules that require explicit docking while enriching the docked...

RESEARCH AND CLOUD DEPLOYMENT OF ENHANCED SAMPLING METHODS IN MOVABLETYPE - ABSTRACT THE STUDY OF PROTEIN/LIGAND BINDING IS ONE OF THE CENTRAL PROBLEMS IN COMPUTATIONAL BIOLOGY BECAUSE OF ITS IMPORTANCE IN UNDERSTANDING INTERMOLECULAR INTERACTIONS, AND BECAUSE OF ITS PRACTICAL PAYOFF IN DRUG DISCOVERY EFFORTS. THE TRANSFORMATIVE IMPACT ACCURATE TARGET/LIGAND STRUCTURE CAN HAVE IN THE DESIGN OF NEXT GENERATION MEDICINES CANNOT BE OVERSTATED. IF WE COULD ROUTINELY AND ACCURATELY DESIGN MOLECULES USING THESE APPROACHES IT WOULD REVOLUTIONIZE DRUG DISCOVERY BY WINNOWING OUT COMPOUNDS WITH NO ACTIVITY WHILE FOCUSING MORE EFFORT AND SCRUTINY ON HIGHLY ACTIVE COMPOUNDS. IN THIS PROPOSAL WE DESCRIBE A NOVEL METHOD WE CALL MOVABLETYPE (MT) THAT FOR THE FIRST TIME WILL BE COUPLED WITH CUTTING EDGE ENHANCED MOLECULAR DYNAMICS (MD) METHODS (E.G., SIMULATED TEMPERING, ACCELERATED MD, METADYNAMICS, AND REPLICA EXCHANGE MD) IN AIMS I.1 AND II.1A, LINEAR SCALING QUANTUM MECHANICS (FOR IMPROVED ELECTROSTATICS) IN AIM I.2, AND A NEW MONTE CARLO SAMPLING REGIME CALLED CONSECUTIVE HISTOGRAMS MONTE CARLO (CHMC) IN AIM II.1B FOR INCREASED SPEED. WE EXPECT THIS DEVELOPMENT TO SIGNIFICANTLY EXPAND THE DOMAIN APPLICABILITY OF MT IN PARTICULAR (AND FREE ENERGY METHODS IN GENERAL) TO INCLUDE THOSE SITUATIONS WHICH REQUIRE GREATER CONFORMATIONAL SAMPLING THAN CAN BE PROVIDED BY DOCKING ALONE. MT ADDRESSES THE PROTEIN LIGAND BINDING AND SCORING PROBLEM USING FUNDAMENTAL STATISTICAL MECHANICS COMBINED WITH A NEW WAY TO GENERATE THE ENSEMBLE OF A LIGAND IN A PROTEIN BINDING POCKET. VIA A RAPID ASSEMBLY OF THE NECESSARY PARTITION FUNCTIONS, WITH MT WE DIRECTLY OBTAIN ABSOLUTE BINDING FREE ENERGIES AND THE LOW FREE ENERGY POSES (VERSUS MOST CONVENTIONAL FREE ENERGY METHODS IN COMMERCIAL/INDUSTRIAL LABS WHICH USUALLY OBTAIN RELATIVE BINDING FREE ENERGIES). CONCEPTUALLY, THE MT METHOD IS ANALOGOUS TO BLOCK AND TYPE SET PRINTING, WHICH ALLOWS US TO EFFICIENTLY EVALUATE PARTITION FUNCTIONS DESCRIBING REGIONS OR SYSTEMS OF INTEREST. OVERALL, THE MT METHOD IS A GENERAL ONE AND CAN USE A BROAD RANGE OF TWO-BODY POTENTIAL FUNCTIONS AND CAN BE EXTENDED TO HIGHER-ORDER INTERACTIONS IF SO DESIRED. RECENT WORK WITH THE MT METHOD HAS LED TO THE LAUNCH OF THREE CORE PRODUCT MODULES: MTSCORE (BOTH END STATE AND ENSEMBLE-BASED BINDING AFFINITY PREDICTION), MTDOCK (LIGAND PLACEMENT), AND MTCS (LIGAND CONFORMATIONAL SEARCH). IN THIS PROJECT, WE WILL EXTEND OUR MT PRODUCT LINE BY OPTIMIZING THE METHOD FOR USE WITH ADVANCED SAMPLING TECHNIQUES AND DELIVER THIS METHODOLOGY TO COMPUTATIONAL CHEMISTS FOR USE IN THEIR INDUSTRIAL STRUCTURE-BASED DRUG DESIGN CAMPAIGNS. THIS WORK WILL INVOLVE DEVELOPMENT OF A NEW, INTEGRATED TOOL FOR AUTOMATED STRUCTURE/MODEL PREPARATION, INTEGRATION WITH AND OPTIMIZATION FOR SEVERAL MOLECULAR DYNAMICS ENGINES, ADDITION AN UPDATED ELECTROSTATICS ENGINE (BUILT ON OUR MATURE, LINEAR SCALING, SEMI-EMPIRICAL QUANTUM MECHANICS INFRASTRUCTURE), DEVELOPMENT OF A NEW MONTE CARLO METHOD FOR INCREASED SPEED, AND CLOUD-BASED DEPLOYMENT ON THE GRIDMARKETS PLATFORM (AIM II.2). FINALLY, IN AIM II.3, WE WILL COMMERCIALLY DEPLOY THE TECHNOLOGY, CONSTRUCT GRAPHICAL USER INTERFACES FOR USE IN MOE, AND VALIDATE ITS USE IN REAL LIFE STRUCTURE-BASED DRUG DISCOVERY PROBLEMS WITH OUR PHARMACEUTICAL COLLABORATORS (SEE LETTERS OF SUPPORT).

Posted 5/5/23, 12:00 AM